{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
Collegium Pharmaceutical, Inc. has adjusted its valuation, showcasing a favorable P/E ratio of 15 and strong profitability metrics, including a ROCE of 16.93% and ROE of 28.03%. The company has outperformed the S&P 500 in stock returns over both year-to-date and annual periods, highlighting its competitive market position.
Collegium Pharmaceutical Hits Day High with 13.7% Surge in Stock Price
Collegium Pharmaceutical, Inc. has seen notable stock activity, with a significant increase today and strong weekly and monthly gains. Despite its annual performance exceeding that of the S&P 500, the company faces challenges, including a low EBIT to Interest ratio and a decline in pre-tax profit in its latest quarterly results.
Collegium Pharmaceutical Hits New 52-Week High at $41.81
Collegium Pharmaceutical, Inc. achieved a new 52-week high of USD 41.81 on November 6, 2025, reflecting strong performance over the past year. The company, with a market cap of USD 1,222 million, has shown a one-year growth of 22.07%, outperforming the S&P 500. Key metrics indicate solid financial health despite a high debt-to-equity ratio.
Is Collegium Pharmaceutical, Inc. technically bullish or bearish?
As of October 31, 2025, Collegium Pharmaceutical, Inc. shows a bullish technical trend with strong daily moving averages and mixed signals from MACD and Dow Theory, having outperformed the S&P 500 recently but lagging over the past year and five years.
Collegium Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics
Collegium Pharmaceutical, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $36.10. The company has experienced significant volatility over the past year, with a high of $39.95 and a low of $23.23, while showing mixed technical indicators and notable performance relative to the S&P 500.
Is Collegium Pharmaceutical, Inc. technically bullish or bearish?
As of October 31, 2025, Collegium Pharmaceutical, Inc. is in a bullish trend supported by positive moving averages and Bollinger Bands, though caution is advised due to a mildly bearish MACD signal, despite outperforming the S&P 500 recently.
Collegium Pharmaceutical Experiences Revision in Stock Evaluation Amid Strong Market Performance
Collegium Pharmaceutical, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 15 and a price-to-book value of 4.25. The company exhibits strong operational efficiency with a return on equity of 28.03% and a year-to-date stock performance of 25.65%, surpassing the S&P 500.
Is Collegium Pharmaceutical, Inc. technically bullish or bearish?
As of October 31, 2025, Collegium Pharmaceutical, Inc. has a bullish technical trend, supported by positive daily moving averages and monthly indicators, while outperforming the S&P 500 year-to-date with a return of 25.65%.
Is Collegium Pharmaceutical, Inc. technically bullish or bearish?
As of October 31, 2025, Collegium Pharmaceutical, Inc. shows a bullish technical trend, supported by positive daily moving averages and monthly MACD, despite some caution from weekly indicators, with a year-to-date return of 25.65% compared to the S&P 500's 16.30%.
Collegium Pharmaceutical Experiences Revision in Its Stock Evaluation Amidst Market Dynamics
Collegium Pharmaceutical, Inc. has recently adjusted its valuation, with a P/E ratio of 15 and a Price to Book Value of 4.25. The company shows strong operational performance, reflected in its ROCE of 16.93% and ROE of 28.03%, and has outperformed the S&P 500 over three years.
Collegium Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics
Collegium Pharmaceutical, Inc. has recently seen a stock price adjustment, currently at $34.41. Over the past year, it reached a high of $42.29 and a low of $23.23. The company has outperformed the S&P 500 year-to-date but faced a decline in the past month, reflecting market volatility.
Collegium Pharmaceutical, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Collegium Pharmaceutical, Inc. has recently seen a stock price adjustment, currently at $35.75. The company has experienced significant volatility over the past year, with a 52-week high of $42.29 and a low of $23.23. Its performance has varied, showing strong returns over three years compared to the S&P 500.
Is Collegium Pharmaceutical, Inc. technically bullish or bearish?
As of August 8, 2025, Collegium Pharmaceutical, Inc. shows a bullish technical trend supported by positive MACD and moving averages, though mixed signals from KST and Dow Theory suggest caution, especially as the stock has underperformed the S&P 500 recently while outperforming it year-to-date.
Is Collegium Pharmaceutical, Inc. overvalued or undervalued?
As of August 28, 2025, Collegium Pharmaceutical, Inc. is considered overvalued due to its lower P/E ratio of 15 compared to the peer average of 22.77, an EV to EBITDA ratio of 4.89 versus 5.28, and a Price to Book Value of 4.25, alongside a recent 1-year return of -6.76% that lags behind the S&P 500's 17.14%.
Is Collegium Pharmaceutical, Inc. overvalued or undervalued?
As of May 8, 2025, Collegium Pharmaceutical, Inc. is fairly valued with a P/E ratio of 15, an EV to EBITDA of 4.89, and a ROE of 28.03%, despite underperforming the S&P 500 over the past year.
Is Collegium Pharmaceutical, Inc. technically bullish or bearish?
As of June 11, 2025, the technical trend is mildly bearish, supported by daily moving averages and monthly indicators, despite some conflicting signals from weekly metrics.
Who are in the management team of Collegium Pharmaceutical, Inc.?
As of March 2022, the management team of Collegium Pharmaceutical, Inc. includes Chairman Michael Heffernan, CEO Joseph Ciaffoni, Lead Independent Director Gino Santini, and several independent directors: Rita Balice-Gordon, Garen Bohlin, John Fallon, and John Freund. They are responsible for the company's strategic direction and governance.
What does Collegium Pharmaceutical, Inc. do?
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing abuse-deterrent products for chronic pain treatment. As of March 2025, it reported net sales of $178 million and a market cap of approximately $971.56 million.
How big is Collegium Pharmaceutical, Inc.?
As of Jun 18, Collegium Pharmaceutical, Inc. has a market capitalization of 971.56 million, with net sales of 664.29 million and a net profit of 43.91 million over the latest four quarters. The company's balance sheet shows shareholder's funds of 228.84 million and total assets of 1,663.59 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
